INS and metabolic syndrome: This observation is in contrast with findings that hypogonadal men and men who underwent androgen deprivation therapy are characterized by increased body weight, increased total fat mass, impaired insulin sensitivity, and are more prone to the development of metabolic syndrome and type 2 diabetes, while testosterone replacement therapy improves glycemic control, increases insulin sensitivity, decreases BMI and visceral fat mass, as well as reduces total and LDL cholesterol levels [46, 47].